Vitrolife Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Vitrolife wird ein jährliches Gewinn- und Umsatzwachstum von 96.8% bzw. 8.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 96.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 5.2% betragen.

Wichtige Informationen

96.8%

Wachstumsrate der Gewinne

96.7%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	45.7%
Wachstumsrate der Einnahmen	8.2%
Zukünftige Eigenkapitalrendite	5.2%
Analystenabdeckung	Low
Zuletzt aktualisiert	15 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Vitrolife AB (publ) Just Beat EPS By 16%: Here's What Analysts Think Will Happen Next

Jul 20

Vitrolife AB (publ) Just Missed Earnings; Here's What Analysts Are Forecasting Now

Feb 05

Recent updates

Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)

Aug 21

Vitrolife AB (publ) Just Beat EPS By 16%: Here's What Analysts Think Will Happen Next

Jul 20

Vitrolife AB (publ) (STO:VITR) Shares Fly 32% But Investors Aren't Buying For Growth

Jul 18

Vitrolife (STO:VITR) Is Carrying A Fair Bit Of Debt

Apr 03

A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Mar 07

Vitrolife AB (publ) Just Missed Earnings; Here's What Analysts Are Forecasting Now

Feb 05

An Intrinsic Calculation For Vitrolife AB (publ) (STO:VITR) Suggests It's 27% Undervalued

Aug 25

Vitrolife (STO:VITR) Could Easily Take On More Debt

Aug 03

Are Vitrolife AB (publ) (STO:VITR) Investors Paying Above The Intrinsic Value?

May 26

Is Vitrolife (STO:VITR) A Risky Investment?

Jan 23

Vitrolife (STO:VITR) Seems To Use Debt Quite Sensibly

Oct 18

Calculating The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Sep 09

Is Vitrolife (STO:VITR) A Risky Investment?

Jul 07

A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)

May 26

Vitrolife (STO:VITR) Seems To Use Debt Rather Sparingly

Mar 31

Estimating The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Feb 07

Gewinn- und Umsatzwachstumsprognosen

OM:VITR - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (SEK Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	4,265	763	983	1,134	4
12/31/2025	3,912	662	896	1,011	4
12/31/2024	3,588	527	772	962	4
9/30/2024	3,555	-3,805	649	811	N/A
6/30/2024	3,535	-3,799	671	819	N/A
3/31/2024	3,499	-3,836	655	795	N/A
12/31/2023	3,512	-3,851	638	757	N/A
9/30/2023	3,462	402	650	752	N/A
6/30/2023	3,412	388	652	738	N/A
3/31/2023	3,336	412	631	706	N/A
12/31/2022	3,234	394	549	636	N/A
9/30/2022	2,893	353	366	470	N/A
6/30/2022	2,501	349	288	377	N/A
3/31/2022	2,054	305	249	331	N/A
12/31/2021	1,681	341	321	384	N/A
9/30/2021	1,549	415	525	555	N/A
6/30/2021	1,464	399	515	545	N/A
3/31/2021	1,291	325	455	479	N/A
12/31/2020	1,246	287	336	356	N/A
9/30/2020	1,273	276	278	303	N/A
6/30/2020	1,331	294	332	361	N/A
3/31/2020	1,502	377	315	399	N/A
12/31/2019	1,480	383	326	413	N/A
9/30/2019	1,391	371	210	412	N/A
6/30/2019	1,297	339	93	344	N/A
3/31/2019	1,199	324	199	341	N/A
12/31/2018	1,151	310	169	349	N/A
9/30/2018	1,102	294	286	343	N/A
6/30/2018	1,064	284	N/A	341	N/A
3/31/2018	1,066	276	N/A	321	N/A
12/31/2017	1,046	264	N/A	312	N/A
9/30/2017	1,026	255	N/A	281	N/A
6/30/2017	991	234	N/A	243	N/A
3/31/2017	913	211	N/A	204	N/A
12/31/2016	856	190	N/A	181	N/A
9/30/2016	804	188	N/A	197	N/A
6/30/2016	771	196	N/A	210	N/A
3/31/2016	747	186	N/A	196	N/A
12/31/2015	722	183	N/A	194	N/A
9/30/2015	660	154	N/A	138	N/A
6/30/2015	609	137	N/A	132	N/A
3/31/2015	554	122	N/A	130	N/A
12/31/2014	511	109	N/A	146	N/A
9/30/2014	497	96	N/A	145	N/A
6/30/2014	481	77	N/A	121	N/A
3/31/2014	467	67	N/A	111	N/A
12/31/2013	453	56	N/A	106	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: VITR wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (1.2%).

Ertrag vs. Markt: VITR wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: VITR wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: VITRDie Einnahmen des Unternehmens (8.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (0% pro Jahr).

Hohe Wachstumseinnahmen: VITRDie Einnahmen des Unternehmens (8.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: VITRDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (5.2%).

Vitrolife Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 7.2% to kr248

Vitrolife AB (publ) Just Beat EPS By 16%: Here's What Analysts Think Will Happen Next

Vitrolife AB (publ) Just Missed Earnings; Here's What Analysts Are Forecasting Now

Price target decreased by 8.9% to kr257

Consensus EPS estimates fall by 16%

Price target decreased by 7.4% to kr292

Recent updates

Vitrolife AB (publ) to Report Fiscal Year 2024 Final Results on Mar 27, 2025

Vitrolife AB (publ) to Report Q4, 2025 Results on Jan 29, 2026

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Vitrolife AB (Publ) Announces Election Committee Appointments

Now 20% overvalued after recent price rise

Now 20% overvalued after recent price rise

Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)

Vitrolife AB (publ) to Report Q3, 2025 Results on Oct 29, 2025

Price target increased by 7.2% to kr248

Vitrolife AB (publ) Just Beat EPS By 16%: Here's What Analysts Think Will Happen Next

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Vitrolife AB (publ) (STO:VITR) Shares Fly 32% But Investors Aren't Buying For Growth

Vitrolife AB (publ) (OM:VITR) acquired Stb Zorg B.V.

Director recently bought kr1.6m worth of stock

Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million.

Vitrolife AB (Publ) Approves Dividend for the Financial Year 2023

Upcoming dividend of kr1.00 per share

First quarter 2024 earnings released: EPS: kr0.85 (vs kr0.74 in 1Q 2023)

Now 22% undervalued

Dividend increased to kr1.00

Vitrolife (STO:VITR) Is Carrying A Fair Bit Of Debt

A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Vitrolife AB (publ) Just Missed Earnings; Here's What Analysts Are Forecasting Now

Full year 2023 earnings: EPS misses analyst expectations

Vitrolife AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024

Vitrolife AB (Publ) Reports Non-Cash Impairment for the Fourth Quarter of 2023

Vitrolife AB (publ)'s (STO:VITR) Share Price Matching Investor Opinion

Here's Why We Think Vitrolife (STO:VITR) Is Well Worth Watching

Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)

Is Vitrolife (STO:VITR) A Risky Investment?

Investor sentiment improves as stock rises 21%

Price target decreased by 8.9% to kr257

Third quarter 2023 earnings released: EPS: kr0.90 (vs kr0.80 in 3Q 2022)

Vitrolife AB (publ) Announces Election Committee Appointments

An Intrinsic Calculation For Vitrolife AB (publ) (STO:VITR) Suggests It's 27% Undervalued

Vitrolife AB (publ) Announces Resignation of Maria Forss as Senior Vice President

Insufficient new directors

Vitrolife (STO:VITR) Could Easily Take On More Debt

Vitrolife AB Announces Board Changes

Chief Financial Officer recently bought kr335k worth of stock

Consensus EPS estimates fall by 16%

Price target decreased by 7.4% to kr292

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 15%

Vitrolife AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

Are Vitrolife AB (publ) (STO:VITR) Investors Paying Above The Intrinsic Value?

Chief Financial Officer recently bought kr535k worth of stock

Chief Financial Officer recently bought kr535k worth of stock

Upcoming dividend of kr0.85 per share at 0.4% yield

Full year 2022 earnings: EPS misses analyst expectations

Full year 2022 earnings released: EPS: kr2.91 (vs kr2.98 in FY 2021)

Vitrolife AB (publ) Proposes Dividend for 2022

Vitrolife AB (publ) Announces Executive Changes

Is Vitrolife (STO:VITR) A Risky Investment?

Price target decreased to kr260

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Vitrolife AB (publ) to Report First Half, 2023 Results on Jul 14, 2023

Investor sentiment improved over the past week

Vitrolife (STO:VITR) Seems To Use Debt Quite Sensibly

Vitrolife AB (publ) Announces Election Committee Appointments

Price target decreased to kr307

Now 30% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Vitrolife AB (Publ) Announces Retirement of Thomas Axelsson as CEO

Calculating The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Vitrolife AB (publ), Annual General Meeting, Apr 27, 2023

Is Vitrolife (STO:VITR) A Risky Investment?

A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)